THERACRYF PLC Logo

THERACRYF PLC

Develops sulforaphane-based medicines for behavioural brain disorders and oncology.

TCF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVN2C70 (+2 more)
LEI:
213800NO3E6TSTQO8K20
Country:
United Kingdom
Address:
SUITE 24G13 - BLOCK 24, SK10 4TG NETHER ALDERLEY

Description

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 08:20
Half-year Financial Report
English 203.1 KB
2025-11-26 08:25
Marking Addiction Awareness Week
English 15.6 KB
2025-11-24 08:25
Notice of Results
English 12.5 KB
2025-11-03 08:30
Ox-1 Programme Achieves Manufacturing Milestone
English 16.3 KB
2025-10-10 08:00
World Mental Health Day & Q4 Conference Schedule
English 16.5 KB
2025-09-26 16:45
Holding(s) in Company
English 23.5 KB
2025-09-08 12:38
Holding(s) in Company
English 23.9 KB
2025-09-04 08:00
Ox-1 Patent Grant & Development Programme Update
English 17.3 KB
2025-08-04 16:27
Holding(s) in Company
English 23.3 KB
2025-07-17 08:00
Manufacturing Scale Up of Lead Ox-1 Programme
English 14.1 KB
2025-07-09 16:07
Result of AGM
English 12.3 KB
2025-06-16 17:10
Notice of AGM
English 13.0 KB
2025-06-10 13:32
Ox-1 Investor Presentation
English 11.6 KB
2025-06-03 08:00
Final results for year to 31 March 2025
English 235.9 KB
2025-05-23 08:14
Notice of Results and Ox-1 presentation
English 12.5 KB

Automate Your Workflow. Get a real-time feed of all THERACRYF PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for THERACRYF PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for THERACRYF PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.